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Background: Immunoglobulin E (IgE) has traditionally been associated with
anaphylaxis and atopic disease. Previous studies reported that serum IgE levels are
elevated in nephrotic syndrome and suggested IgE levels as a prognostic indicator in
glomerular diseases. The aim of this study was to explore the association between
serum IgE levels and renal outcome in patients with immunoglobulin A nephrop-
athy (IgAN).
Methods: We included 117 patients with biopsy-proven IgAN. Renal progression
was deﬁned if a patient meets one of these criteria: (1) a negative value of delta
estimated glomerular ﬁltration rate (mL/min/1.73 m2/mo) or (2) a rise in serum
creatinine to an absolute level of  1.3 mg/dL (male) or 1.2 mg/dL (female). We
deﬁned delta changes in serum creatinine, estimated glomerular ﬁltration rate, and
proteinuria as a difference of values during the follow-up period.
Results: A total of 117 patients with IgAN were included. The serum IgE level was
signiﬁcantly high in the renal progressive group compared with the nonprogressive
group. Sex and history of gross hematuria were signiﬁcantly different between the
high-IgE group and the low-IgE group. Regression analysis showed that a male sex,
initial proteinuria, and change of proteinuria were signiﬁcantly associated with
serum IgE levels.
Conclusion: The serum IgE level is potentially associated with disease progression
and pathogenesis of IgAN.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).nal Medicine, Kyung Hee
, Dongdaemun-gu, Seoul
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ty of Nephrology. Published b
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Immunoglobulin A nephropathy (IgAN), characterized by
IgA deposition in glomerular mesangium, is the most common
primary glomerulonephritis (GN) worldwide [1] and the
leading cause of GN in some countries, such as Korea [2].
Recent studies have shown that 35e50% of these patients
exhibit disease progression to end-stage kidney disease withiny Elsevier. This is an open access article under the CC BY-NC-ND license
Table 1. Patient characteristics
Parameters
Number of patients 117
Sex (male) 67 (57.3)
Age (y) 33.4
BMI (kg/m2) 23.1 ± 3.6
Smoking 20 (17.1)
HTN 23 (19.7)
Serum IgE (IU/mL) 304 ± 607
Serum IgA (mg/dL) 334 ± 157
Period of follow-up (mo) 39 ± 33
Hb (g/dL) 13.3 ± 2.0
Albumin (g/dL) 3.8 ± 0.7
Total cholesterol (mg/dL) 186 ± 64
Initial serum Cr (mg/dL) 1.3 ± 1.0
Initial eGFR (mL/min/1.73 m2) 84.8 ± 37.4
Initial UPCR (g/gCr) 1.8 ± 2.7
Final serum Cr (mg/dL) 1.8 ± 3.2
Final eGFR (mL/min/1.73 m2) 90.5 ± 42.0
Final proteinuria (g/gCr) 0.8 ± 1.2
Gross hematuria 27 (23.1)
Renal progression 17 (14.5)
Pathologic stage
Stage I 29 (24.8)
Stage II 62 (53.0)
Stage III 19 (16.2)
Stage IV 6 (5.1)
Stage V 1 (0.9)
Data are presented as n (%) or mean ± SD.
BMI, body mass index; Cr, creatinine; eGFR, estimated glomerular
ﬁltration rate; Hb, hemoglobin; HTN, hypertension; IgA, immunoglob-
ulin A; IgE, immunoglobulin E; UPCR, urine protein-to-creatinine ratio.
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ease: Improving Global Outcomes guideline of 2012, protein-
uria, blood pressure, and kidney biopsy ﬁndings at
presentation are associated with the risk of end-stage renal
disease and the doubling of serum creatinine (SCr) levels [4].
Among these, proteinuria of >1 g/d is a powerful independent
predictor of accelerated decline of renal function [5,6].
Although the pathologic analysis of renal biopsies is the
standard for the diagnosis of IgAN, the measurement of novel
biomarkers in serum might be regarded as an alternative tool,
providing meaningful information for the diagnosis and
prognosis of this glomerular disease [7e11].
Immunoglobulin E (IgE) has traditionally been associated
with anaphylaxis and atopic diseases. IgE production is char-
acteristic of not only allergy but also infection by parasitic
worms. The highest levels of IgE are often associatedwith atopic
dermatitis, followed by atopic asthma, perennial allergic
rhinitis, and seasonal allergic rhinitis. Measurement of total IgE
levels in patients with allergic bronchopulmonary aspergillosis
can be used tomonitor disease activity and response to therapy.
Total serum IgE level has been found tobe of clinical relevance in
nephrotic syndrome, where elevated levels of serum IgE were
regarded as a predictor of the disease [12e14]. However, the
clinical signiﬁcance has rarely been studied in IgAN. The aim of
this studywas to explore the association between the serum IgE
level in IgAN patients and their renal outcome.
Methods
Study population and study design
This is an observational retrospective study of a cohort of
IgAN patients undergoing kidney biopsies, between 1995 and
2012 (Fig. 1). All patients in this study were diagnosed at Kyung
Hee Medical Center and Kyung Hee University Hospital atFigure 1. Study design and renal outcomesGangdong. A total of 117 patients, 67 (57.3%) men and 50
(42.7%) women, with IgANwere included (Table 1). Themedian
age at the time of renal biopsy was 33 years (range, 12e68
years). We collected the data of patients' demographics and
serum IgE levels via routine laboratory examination.. IgAN, immunoglobulin A nephropathy.
Table 2. Comparison between progressive and nonprogressive
patients
Parameters Nonprogressive Progressive P
Patient number 103 14
Sex 55 (53.4) 12 (85.7) 0.010
Age (y) 31.5 ± 13.5 41.6 ± 12.7 0.001
BMI (kg/m2) 22.8 ± 3.4 25.7 ± 3.9 0.004
Smoking 14 (13.6) 6 (42.9) 0.019
HTN 15 (14.6) 8 (57.1) < 0.001
Initial serum IgE
(IU/mL)
238 ± 290 590 ± 1,247 0.014
Initial serum IgA
(mg/dL)
330 ± 155 346 ± 168 0.685
Initial Hb (g/dL) 13.5 ± 1.9 12.4 ± 2.3 0.018
Initial serum Cr
(mg/dL)
1.1 ± 0.8 2.1 ± 1.3 < 0.001
Initial eGFR
(mL/min/1.73 m2)
91.8 ± 33.8 54.4 ± 37.1 < 0.001
Initial proteinuria
(g/gCr)
1.4 ± 2.2 3.4 ± 3.8 0.002
Final proteinuria
(g/gCr)
0.6 ± 1.0 2.7 ± 1.5 < 0.001
Delta serum Cr
(mg/dL)
e0.01 ± 0.04 0.1 ± 0.2 < 0.001
Delta eGFR
(mL/min/1.73 m2)
0.8 ± 2.7 e0.6 ± 0.7 0.014
Delta proteinuria
(g/gCr)
e0.03 ± 0.08 e0.04 ± 0.09 0.544
Pathologic stage 2.0 ± 0.8 2.3 ± 1.0 0.152
Gross hematuria 25 (24.2) 3 (21.4) 0.549
Use of
immunosuppressants
8 (7.8) 6 (42.9) < 0.001
Data are presented as n (%) or mean ± SD.
BMI, body mass index; Cr, creatinine; eGFR, estimated glomerular
ﬁltration rate; Hb, hemoglobin; HTN, hypertension; IgA, immunoglob-
ulin A; IgE, immunoglobulin E.
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We retrospectively analyzed the correlation between the
serum IgE level and clinical parameters (age, sex, SCr, estimated
glomerular ﬁltration rate [eGFR], proteinuria, blood pressure,
and history of gross hematuria). The eGFR was calculated using
the Modiﬁcation of Diet in Renal Disease formula:
[eGFR ¼ 175  standardized SCre1.154  agee0.203  0.741 (if
Asian) 0.742 (if female)] [15]. Serum total IgE was determined
by high-sensitivity nephelometry (BN II System; Siemens
Healthcare Diagnostics, Deerﬁeld, IL, USA).
Deﬁnition of renal progression
The initialmeasurementof SCrwasobtainedat the timeof the
renal biopsy. The SCr measured at the last follow-up visit was
used when deﬁning IgAN progression. SCr values were consid-
ered normal if they were 1.2 mg/dL. We deﬁned delta changes
in SCr, eGFR, and proteinuria as follows: delta SCr (mg/dL/
mo)¼ [(ﬁnal SCr levele initial SCr level)/duration of follow-up],
delta eGFR (mL/min/1.73 m2/mo) ¼ [(ﬁnal eGFR level e initial
eGFR level)/duration of follow-up], and delta proteinuria (g/gCr/
mo) ¼ [(ﬁnal urine protein level e initial urine protein level)/
durationof follow-up]. Renal progressionwasdeﬁned if a patient
meets one of these criteria: (1) a negative value of delta eGFR
(mL/min/1.73 m2/mo) or (2) a rise in SCr to an absolute level of
 1.3 mg/dL (male) or 1.2 mg/dL (female).
Statistical methods
Continuous variables are expressed as the mean ± standard
deviation or median (interquartile range). Differences between
the 2 groups were assessed using the Student t test; the c2 test
was used for categorical variables. To evaluate the association
between serum IgE and clinical variables, we used a
univariate linear regression model. A P value < 0.05 was
considered statistically signiﬁcant. The statistical analysis was
performed with the SPSS program for Windows (version 14.0;
SPSS Inc., Chicago, IL, USA).
Results
Baseline clinical characteristics
A total of 117 patients were enrolled in this study. Among the
patients, 67 were male (57.3%) and 50 were female (42.7%). The
mean agewas 33.4± 13.0 years, and themean follow-up period
was 39 ± 33 months. The mean initial eGFR and urine protein
creatinine values were 84.8 ± 37.0 mL/min/1.73 m2 and
1.8 ± 2.7 g/gCr, respectively. The distribution in glomerular
grades of the 117 patients, using the H.S. Lee grading, was as
follows: grade I, 29 patients (24.8%); grade II, 62 patients
(53.0%); grade III, 19 patients (16.2%); grade IV, 6 patients
(5.1%); and grade V, 1 patient (0.9%). The mean level of serum
IgE was 304 ± 607 IU/mL (Table 1).
Progression of IgAN
Among 117 patients, 86 (73.5%) had normal SCr levels and 31
(26.5%) had elevated levels at the time of the renal biopsy. IgAN
progression was found in 14 of the 117 patients (12%). Patients
with progression had initially higher levels of serum IgE, SCr,and proteinuria and frequently had a history of hypertension
and use of immunosuppressants (Table 2). End-stage renal
disease (requiring dialysis or kidney transplantation) devel-
oped in 8 patients (6.8%).
Correlations between serum IgE and clinical variables
The serum IgE level was signiﬁcantly high in the renal pro-
gressive group compared with the nonprogressive
group (801 ± 1,520 vs. 236 ± 293 IU/mL, P < 0.001; Table 2).
Male sex (70.0% vs. 43.9%, P ¼ 0.004) was signiﬁcantly different
between the high-IgE group and the low-IgE group. However,
no signiﬁcant differences were seen for delta SCr (mg/dL/mo),
delta eGFR (mL/min/1.73 m2/mo), delta proteinuria (g/gCr/mo),
and pathologic ﬁndings (Table 3). Univariate linear regression
analysis showed that male sex (standardized b ¼ 0.308,
t¼ 2.246, P¼ 0.028), initial proteinuria (standardized b¼ 0.617,
t ¼ 2.712, P ¼ 0.008), ﬁnal proteinuria (standardized b ¼ 0.321,
t ¼ 3.086, P ¼ 0.003), and delta proteinuria (standardized
b ¼ 0.404, t ¼ 2.246, P ¼ 0.028) were signiﬁcantly associated
with serum IgE levels (Table 4).
Discussion
The present study showed that the serum IgE level was
signiﬁcantly high in the renal progressive group comparedwith
the nonprogressive group. Serum IgE were also positively
correlated with initial and delta proteinuria.
IgE has the lowest abundance in vivo, and its levels are
tightly regulated. Concentrations of free serum IgE are
Table 4. Clinical variables for association with serum IgE (linear
regression model)
Parameters Standardized b t P
Albumin (g/L) e0.058 e0.402 0.689
Hb (g/dL) e0.105 e0.723 0.472
Sex (male, %) 0.308 2.272 0.028
Age (y) e0.032 e0.218 0.828
Initial serum Cr (mg/dL) e0.137 e0.767 0.445
Initial eGFR (mL/min/1.73 m2) e0.185 e0.941 0.350
Initial proteinuria (g/gCr) 0.616 2.719 0.008
Final proteinuria (g/gCr) 0.321 3.086 0.003
Delta serum Cr (mg/dL) 0.084 0.638 0.525
Delta eGFR (mL/min/1.73 m2) 0.145 1.058 0.293
Delta proteinuria (g/gCr) 0.404 2.417 0.028
Serum IgA (mg/dL) 0.584 0.584 0.561
Gross hematuria (%) e1.026 e1.026 0.308
Systolic blood pressure (mmHg) e0.472 0.638 0.638
Pathologic stage e1.864 0.066 0.066
Cr, creatinine; eGFR, estimated glomerular ﬁltration rate; Hb, hemo-
globin; IgA, immunoglobulin A; IgE, immunoglobulin E.
Table 3. Comparison of clinical variables according to the levels of
plasma IgE in patients with IgAN
Parameters IgE < 109 IU/mL IgE  109 IU/mL P
Patient number 57 60
Albumin (g/L) 3.8 ± 0.5 3.7 ± 0.8 0.503
Hb (g/dL) 13.1 ± 2.0 13.5 ± 2.1 0.296
Sex 25 (43.9) 42 (70.0) 0.004
Age (y) 34.3 ± 12.4 32.6 ± 14.7 0.501
BMI (kg/m2) 22.9 ± 3.8 23.3 ± 3.4 0.623
Smoking 8 (14.0) 12 (20) 0.394
HTN 10 (17.5) 13 (21.7) 0.578
Initial serum Cr (mg/dL) 1.2 ± 0.8 1.4 ± 1.1 0.169
Initial eGFR
(mL/min/1.73 m2)
86.3 ± 38.2 83.3 ± 36.8 0.663
Initial proteinuria (g/gCr) 1.6 ± 2.6 2.0 ± 2.9 0.467
Final proteinuria (g/gCr) 1.0 ± 1.5 0.7 ± 1.0 0.263
Delta serum Cr (mg/dL) 0.004 ± 0.045 0.022 ± 0.166 0.422
Delta eGFR
(mL/min/1.73 m2)
0.2 ± 1.6 0.9 ± 3.1 0.179
Delta proteinuria (g/gCr) e0.015 ± 0.061 e0.043 ± 0.100 0.068
Initial serum IgA (mg/dL) 327 ± 139 338 ± 173 0.699
Pathology (stage) 2.1 ± 0.8 2.0 ± 0.9 0.571
Gross hematuria 17 (29.8) 6 (10.0) 0.095
Use of
immunosuppressants
6 (10.5) 8 (13.3) 0.644
Renal progression (%) 8 (14.0) 6 (10.0) 0.507
Data are presented as n (%) or mean ± SD.
BMI, body mass index; Cr, creatinine; eGFR, estimated glomerular ﬁltra-
tion rate; Hb, hemoglobin; HTN, hypertension; IgA, immunoglobulin A;
IgAN, IgA nephropathy.
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~1e10 mg/mL of blood for other immunoglobulin isotypes [16].
Increased IgE production has been documented in various
autoimmune, inﬂammatory, and genetic diseases [17,18].
Despite the importance of IgE in allergic pathogenesis and
helminth immunity, the mechanism by which IgE is produced
and regulated is poorly understood. The classic pathway to IgE
switching involves uptake of allergens by dendritic cells,
allowing for the presentation of antigenic determinants to T
cells. The subsequent stimulation of speciﬁc CD4þ T cells leads
to the production of interleukin (IL)-4 and enhanced stimula-
tion of B cells. IL-4 and IL-13 receptors signal to induce Cε
germline transcripts, rearrangement of the IgE genomic locus,
and production of IgE antibodies. IgE typically binds not only to
mast cells and basophils but also to low-afﬁnity receptors on
inﬂammatory cells and platelets, with the release ofinﬂammatory mediators and chemotactic factors, which have
been thought to cause GN. Evidence supporting the role of type
I hypersensitivity in the pathogenesis of GN comes from reports
of high levels of serum IgE and its deposition in the kidney
[19,20] and renal mast cells in IgAN [21].
The exact pathogenesis of IgAN is still not well deﬁned. The
multihit pathogenesis model proposed integrates ﬁndings from
studies of galactose-deﬁcient IgA1, antiglycan response, for-
mation and deposition of IgA1-containing immune complexes,
and mechanisms of immune complexemediated tissue injury.
Recently, a genome-wide association study of IgAN showed the
interpopulationdifferences in genetic risk. Interestingly, the risk
alleles with largest effects tend to have the greatest population
differentiation and contribute most to the observed geographic
patterns. The geospatial distribution of risk alleles is highly
suggestive of multilocus adaptation, and the genetic risk cor-
relates strongly with variation in local pathogens, particularly
helminth diversity [22]. The enhanced IgA response, conferred
by genome-wide association study risk alleles, is likely protec-
tive against these pathogens, but it can also explain the associ-
ation of mucosal infections as a common trigger for IgAN. Given
the fact that one of the main functions of IgE is providing im-
munity to parasites, such as helminths like Schistosomamansoni
[23] and Trichinella spiralis [24], it is possible that the correlation
of the serum IgE level and IgANprogression in this study reﬂects
how intestinal worm infections pertain to the pathogenesis of
IgAN. Immunologic explanations have been proposed for both
the suppression and induction of allergic diseases by helminth
infection [25e27]. However, our study did not assess the
mechanism of altered production of IgE in IgAN and disease
progression;hence, such furtherprospective studies areneeded.
Our study has certain important limitations. First, factors,
such as allergic diseases, autoimmune disorders, and parasitic
infections, are causes of elevated serum IgE [28]. Unfortunately,
this study did not evaluate these factors besides IgAN. Second,
the number of enrolled patients with IgAN was small, and the
follow-up duration was varied and too short in some cases.
Further study is required with large number and long-term
follow-up. Third, multivariate analysis for risk factors for IgAN
progression could not be performed because of the small
number of disease progression events. Fourth, the retrospective
nature of our study raises the possibility of biases in patient
selection and does not deﬁnitively show that serum IgE itself
caused the disease and/or its progression because of the
observational study design.
In conclusion, the present study shows that the serum IgE
level is elevated in a renal progression group of IgAN patients,
suggesting that the serum IgE level is associated with renal
progression in IgAN patients. Future prospective and controlled
studies are needed to elucidate immunopathogenesis of the
increased serum IgE level in IgAN.
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